- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01393808
Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes (PROCEED)
A Prospective, Randomized, Cross-over, Double-blind, Placebo-controlled Study to Assess the Antiproteinuric Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low or High Sodium Diet and Stable Ras Inhibitor Therapy
Proteinuria is an independent risk factor for cardiovascular morbidity and mortality and for renal disease progression. More proteinuria is associated with faster progression, whereas treatments that reduce proteinuria are renoprotective in both diabetic and non diabetic chronic kidney disease. Of note, lower the residual proteinuria achieved by treatment slower is the disease progression in the long term. On the basis of the above findings, proteinuria has become a target of renoprotective therapy.
Among different antihypertensive medications, those that inhibit the Renin Angiotensin System, such as angiotensin converting enzyme (ACE)inhibitors and angiotensin receptor blockers (ARBs), are those that at comparable blood pressure control, more effectively reduce proteinuria and slow renal disease progression. Thus they have become the key component of renoprotective therapy in patients with proteinuric chronic kidney disease. Observational studies found that their effectiveness, however, is limited or even fully blunted in patients who eat large amount of salt.
Experimental evidence indicates a renoprotective role of the vitamin D system in chronic renal disease. A recent randomized, controlled trial, add-on therapy with selective Vitamin D receptor activator paricalcitol showed an additive antiproteinuric effect in subjects with type 2 diabetes and chronic kidney disease on background Renin-angiotensin-system inhibitor therapy. This effect, however, was largely restricted to subjects with daily sodium intake exceeding 12 grams and was negligible in those with lower sodium intake. Thus, treatment with paricalcitol appears to be effective in particular in those patients who do not appreciably benefit of renin angiotensin system (RAS) inhibitors therapy because of high salt intake. Thus, whether the antiproteinuric effect of paricalcitol is modified by concomitant salt intake in patients with chronic kidney disease (CKD) on background RAS inhibitors therapy, is worth investigating.
The broad aim of this study is to evaluate the interaction between paricalcitol therapy and sodium intake in type 2 diabetes patients with proteinuric kidney disease on stable background RAS inhibitor therapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Bergamo, Italien
- Azienda Ospedaliera Ospedali Riuniti di Bergamo
-
-
BG
-
Romano di Lombardia, BG, Italien
- Azienda Ospedaliera di Treviglio e Caravaggio - Unit of Diabetology and Metabolic Diseases
-
Seriate, BG, Italien
- Azienda Ospedaliera Bolognini - Unità di Medicina
-
Treviglio, BG, Italien
- Azienda Ospedaliera di Treviglio e Caravaggio - Unit of Diabetology and Metabolic Diseases
-
-
Bergamo
-
Brembate, Bergamo, Italien, 24030
- ASL of Ponte San Pietro - Diabetologic Unit
-
Ranica, Bergamo, Italien, 24020
- Clinical Research Center fo Rare Diseases Aldo and Cele Daccò
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male and female patients;
- Age > 18 years;
- Type 2 diabetes patients on low or high sodium diet and stable RAS inhibitor therapy with the following conditions:
Urinary albumin excretion (UAE) rate >300mg/24 hours (200 mcg/min); Serum creatinine <2 mg/dL, PTH ≥ 20 mEq/L and <110 mEq/L; Calcium and phosphorus levels < 9.5 mg/dl and < 5mg/dl, respectively; Controlled BP (systolic/diastolic <140/90 mmHg) while on stable RAS inhibitor therapy;
- Written informed consent.
Exclusion Criteria:
- Previous Vitamin D or Vitamin D analogs therapy (within 3 months prior to the study entry);
- Evidence of toxicity to Vitamin D;
- History of kidney stones;
- Poorly controlled Diabetes: Hb1Ac > 12%;
- Therapy with calcitonin, bisphosphonates, cinacalcet, glucocorticoids, immunosuppressive drugs or other drug that may affect calcium or bone metabolism;
- Cancer and any severe systemic disease or clinical condition that may jeopardize data interpretation or completion of the study;
- Any clinically relevant conditions that might affect study participation and/or study results;
- Any contraindication to be exposed to Paricalcitol;
- Pregnancy or lactating;
- Women of childbearing potential without following a scientifically accepted form of contraception;
- Legal incapacity.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: placebo
|
1-month Placebo Treatment
|
Experimentell: Paricalcitol
|
1-month Paricalcitol 2mcg/day
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Changes in urinary albumin excretion from baseline at 4 month.
Tidsram: At baseline and 1,2,3 and 4 month.
|
At baseline and 1,2,3 and 4 month.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Ambulatory and 24-hour blood pressure profile.
Tidsram: At 1 month.
|
At 1 month.
|
Ambulatory and 24-hour blood pressure profile.
Tidsram: At 2 month.
|
At 2 month.
|
Ambulatory and 24-hour blood pressure profile.
Tidsram: At 3 month.
|
At 3 month.
|
Ambulatory and 24-hour blood pressure profile.
Tidsram: At 4 month.
|
At 4 month.
|
Samarbetspartners och utredare
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- Prabhu RA, Saraf K. Vitamin D in diabetic nephropathy. J Postgrad Med. 2018 Jan-Mar;64(1):5-6. doi: 10.4103/jpgm.JPGM_311_17. No abstract available.
- Parvanova A, Trillini M, Podesta MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PROCEED
- 2011-001713-14 (EudraCT-nummer)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Diabetes typ 2
-
Jiangsu HengRui Medicine Co., Ltd.Avslutad
-
Bnai Zion Medical CenterOkänd
-
Mathias Ried-LarsenAvslutadDiabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitusDanmark
-
Shanghai HEP Pharmaceutical Co., Ltd.Indragen
-
Wang SiqiChina-Japan Friendship HospitalHar inte rekryterat ännu
-
HighTide Biopharma Pty LtdRekryteringTyp 2-diabetes mellitusKina
-
Nanjing First Hospital, Nanjing Medical UniversityRekryteringTyp 2 diabetes mellitusKina
-
BiolingusChinese University of Hong KongRekrytering
-
Eli Lilly and CompanyAktiv, inte rekryterandeTyp 2-diabetes mellitusKina, Förenta staterna, Nederländerna, Spanien, Australien, Österrike, Indien, Kanada, Taiwan, Japan, Storbritannien, Belgien, Frankrike, Tyskland, Mexiko, Rumänien, Italien, Argentina, Brasilien, Puerto Rico, Ukraina, Ungern, Tjeckien, Kalk... och mer
-
HighTide Biopharma Pty LtdShenzhen HighTide Biopharmaceutical Ltd.Avslutad
Kliniska prövningar på Paricalcitol
-
Abramson Cancer Center of the University of PennsylvaniaAvslutad
-
AbbottAvslutadNjurinsufficiens, kroniskFörenta staterna, Polen
-
Cedars-Sinai Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekryteringKronisk pankreatitFörenta staterna
-
Chengdu Suncadia Medicine Co., Ltd.Har inte rekryterat ännu
-
Cedars-Sinai Medical CenterAbbottAvslutadMyelodysplastiska syndrom | LeukemiFörenta staterna
-
Oslo University HospitalAvslutad
-
AbbottAvslutadNjurinsufficiens, kroniskFörenta staterna, Polen
-
AbbottAvslutadNjursjukdom i slutskedet | Sekundär hyperparatyreosFörenta staterna
-
Chinese University of Hong KongIndragen
-
Dr. Reddy's Laboratories LimitedAvslutad